Trial ID or NCT#

NCT01614457

Status

RECRUITING

Purpose

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Eligibility Criteria

Ages Eligible for Study: Older than 6 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Richard B. Moss
Professor of Pediatrics at the Lucile Salter Packard Children's Hospital, Emeritus

Contact us to find out if this trial is right for you.

CONTACT

Angela Leung
(650) 723-5193